Market Place
Company
Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme. 
X
Details:
Rallybio plans to prosecute preclinical activities for KY1066/RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development.
Lead Product(s): RLYB331
Therapeutic Area: Hematology Product Name: KY1066
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Rallybio
Deal Size: Undisclosed Upfront Cash: $3.0 million
Deal Type: Licensing Agreement May 10, 2022
DDF Summit 2022 US
Not Confirmed
Contact SupplierDetails:
Company announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001able to rapidly and effectively restore coagulation in the presence of FXa DOAC, the Trial will assess safety, tolerability, PK and PD.
Lead Product(s): VMX-C001
Therapeutic Area: Hematology Product Name: VMX-C001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
CANbridge is developing CAN106, in conjunction with WuXi Biologics (2269.HK), a global company with leading open-access biologics technology platforms, as part of a strategic partnership for the development of rare disease therapeutics.
Lead Product(s): CAN106
Therapeutic Area: Hematology Product Name: CAN106
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: WuXi Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020
Details:
The FDA provided feedback for ARCA's clinical development plans for evaluating AB201 as a potential treatment for patients with severe COVID-19.
Lead Product(s): rNAPc2
Therapeutic Area: Hematology Product Name: AB201
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
ARCA anticipates that the net proceeds from this offering will be used to initiate its clinical trial of AB201 and for working capital and general corporate purposes.
Lead Product(s): rNAPc2
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: JonesTrading Institutional Services
Deal Size: $9.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 01, 2020
Details:
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19.
Lead Product(s): rNAPc2
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
